MergerApr 30, 2026, 05:27 PM
COEP completes Z Squared merger, rebrands to Z Squared Inc.; divests biopharma ops
AI Summary
Coeptis Therapeutics Holdings, Inc. completed its merger with Z Squared Inc. on April 24, 2026, with Z Squared surviving as a wholly-owned subsidiary. Following the merger, Coeptis changed its name to Z Squared Inc. (Pubco). Concurrently, Coeptis divested substantially all of its biopharmaceutical operations through a spin-out to its stockholders, retaining GEAR Therapeutics, Inc. as a subsidiary. The pro forma financials reflect a significant reduction in assets and liabilities for the remaining entity, along with a reduced net loss.
Key Highlights
- Coeptis completed its merger with Z Squared Inc. on April 24, 2026.
- Coeptis Therapeutics Holdings, Inc. changed its name to Z Squared Inc. (Pubco).
- Substantially all biopharmaceutical operations were spun out to Coeptis stockholders.
- Coeptis' pro forma total assets decreased from $16.15 million to $2.85 million post-spin-out.
- Coeptis' pro forma total liabilities decreased from $2.09 million to $0.82 million post-spin-out.
- Pro forma net loss for 2025 decreased from $(12.28 million) to $(9.12 million) for remaining Coeptis.
- Spin Out Sub received 1,000,000 shares of Coeptis Common Stock.
- Spin Out Sub received an option to acquire GEAR Therapeutics, Inc.